Down-regulation of endometrial matrix metalloproteinase-3 and -7 expression in vitro and therapeutic regression of experimental endometriosis in vivo by a novel nonsteroidal progesterone receptor agonist, tanaproget

Kaylon L Bruner-Tran, Kaylon L. Bruner‐Tran, Zhiming Zhang, Zhang Z, Eisenberg E, Esther Eisenberg, Richard C. Winneker, Winneker RC, Osteen KG, Kevin G. Osteen
The Journal of clinical endocrinology and metabolism · 2006 · vol. 91(4) , pp. 1554–1560 · doi:10.1210/jc.2005-2024 · PMID:16418212 · W2072913562
Lab / animal OA: closed CC0 ⤵ 50 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

Tanaproget, a novel nonsteroidal progesterone receptor agonist, reduced endometrial matrix metalloproteinase expression <i>in vitro</i> and regressed experimental endometriosis <i>in vivo</i>.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

CONTEXT: Endometriosis, the growth of endometrial tissue outside the uterus, is principally an estrogen-dependent disease. In contrast, exposure to progesterone during pregnancy or therapeutically has been shown to provide benefit to some women with this disease. However, recent research suggests that the presence of endometriosis impairs the capacity of the eutopic endometrium to respond to endogenous progesterone. OBJECTIVE: Reduced progesterone responsiveness results in an elevated endometrial expression of matrix metalloproteinases (MMPs) during the secretory phase of the menstrual cycle in women with endometriosis. Although cyclic MMP expression is critical for endometrial growth and remodeling, the failure of progesterone to down-regulate MMPs may impair nidation and promote the invasive establishment of endometriosis. In the current study we examined the ability of a newly developed progesterone receptor (PR) agonist, tanaproget (TNPR), to down-regulate endometrial MMP expression in vitro and regress experimental endometriosis in vivo. SETTING: This study was performed at a university-based medical center. PARTICIPANTS: Asymptomatic volunteers and patients with endometriosis were studied. MAIN OUTCOME MEASURES: We examined the ability of TNPR to down-regulate endometrial MMP expression in vitro compared with that of natural progesterone and two currently marketed synthetic steroidal progestins. Using a human/mouse model of endometriosis, we also tested the in vivo ability of TNPR to regress ectopic lesions established by tissues with reduced progesterone sensitivity. RESULTS: TNPR effectively down-regulated MMP expression in vitro and induced significant reduction of lesions in mice with disease established by tissues from endometriosis patients. CONCLUSION: Given the positive preclinical pharmacological profile of TNPR that has recently been reported, additional development of this compound for the treatment of endometriosis is warranted.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Benzoxazines Benzoxazines Endometriosis Endometrium Matrix Metalloproteinase 3 Matrix Metalloproteinase 7 Receptors, Progesterone Thiones Thiones Adolescent Adolescent Adult Adult Benzoxazines Benzoxazines Blotting, Western Blotting, Western Cells, Cultured Cells, Cultured Down-Regulation

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (24)

Cited by (50)

Source provenance

europepmc
last seen: 2026-10-14T06:08:39.101224+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:03:37.664955+00:00
License: CC0 · commercial use OK